BEAT News & Events

"In just two months since our last earnings call, we made significant progress executing against the commercialization and growth strategy we've consistently discussed over the last several quarters. We established flagship commercial accounts across New York, Dallas, South Florida and Southern California, advanced our heart attack detection and on-demand 12-lead patch initiatives, and strengthened our balance sheet. HeartBeam's differentiated FDA-cleared synthesized 12-lead ECG platform remains the foundation of our growth, backed by strong IP and clinical evidence," said Robert Eno, Chief Executive Officer, HeartBeam. "Looking ahead, we remain focused on expanding our commercial footprint by driving deep adoption within our flagship accounts and continuing to build out workflow integration and patient onboarding within those practices while continuing to make significant advancements with our patch, heart attack detection and AI initiatives throughout 2026."

HeartBeam announced the initiation of a pilot study evaluating its novel on-demand 12-lead ECG patch in patients with suspected coronary artery disease. The study is being conducted at two leading hospitals in Belgrade, Serbia. The initiation of the pilot study represents a significant step in the development of the HeartBeam patch which has the potential to disrupt the long-term continuous monitor and mobile cardiac telemetry markets. The pilot study will enroll approximately 50 patients with a high risk of coronary artery disease whose resting ECGs show no evidence of ischemia. Each participant will undergo exercise stress testing, a standard diagnostic procedure used to identify ischemic changes. Immediately following exercise, patients will activate the HeartBeam patch to generate a synthesized 12-lead ECG, which will be compared directly with a standard 12-lead ECG recorded at the same time. The results will help inform the Company's broader regulatory strategy for the HeartBeam patch.

HeartBeam announced a commercial agreement with Atelier Health, a concierge medical practice led by physicians affiliated with Cedars-Sinai Medical Center. The addition of Beverly Hills-based Atelier Health expands HeartBeam's commercial footprint across four targeted launch markets - New York metro, Dallas, South Florida, and Southern California - completing an initial geographic footprint to advance the Company's scalable go-to-market strategy in concierge and preventive cardiology. "Prevention is foundational to how we care for patients, which requires access to high-quality, meaningful data beyond the clinic," said Dr. Dandillaya. "Our model is built on delivering the highest standard of specialist care with unmatched access and precision, and HeartBeam's technology enables a more proactive, personalized approach to evaluating cardiac symptoms in real-world settings."